高甘油三酯血症性急性胰腺炎的降脂治疗研究进展  

Research advances in lipid-lowering therapy for hypertriglyceridemia pancreatitis with co-morbidities

作　　者：刘润兵 王宗强 毕猛 李洋[3] 郑薇[4] 章晓红 LIU Run-bing;WANG Zong-qiang;BI Meng(Zunyi Medical University,Zunyi 563000,China)

机构地区：[1]遵义医科大学,563000 [2]川北医学院,637000 [3]成都中医药大学,610072 [4]电子科技大学,四川省人民医院急诊科/急诊医学研究室,610072

出　　处：《中国现代药物应用》2024年第5期164-167,共4页Chinese Journal of Modern Drug Application

摘　　要：《高甘油三酯血症性急性胰腺炎诊治急诊专家共识》将高甘油三酯血症性急性胰腺炎(HTG-AP)根据甘油三酯(TG)水平分为两种临床亚型,即高甘油三脂血症(HTG)胰腺炎(血清TG水平>1000 mg/dl;TG水平为500~1000 mg/dl且血清呈乳糜状)、急性胰腺炎(AP)伴HTG(TG水平为150~500 mg/dl)。流行病学表明,富含甘油三酯脂蛋白(TRL)及其残余物是心血管疾病、糖尿病的危险因素,而严重的HTG则增加了胰腺炎的复发风险。因此,针对HTG-AP的早期与长期降TG治疗具有各自特殊性。本文就HTG-AP的研究及降脂治疗新进展作一综述。The Expert Consensus on the Diagnosis and Management of Hypertriglyceridemia Acute Pancreatitis divides hypertriglyceridemic acute pancreatitis(HTG-AP)into two clinical subtypes according to TG levels,namely hypertriglyceridemic(HTG)pancreatitis(serum TG level>1000 mg/dl;TG levels are 500-1000 mg/dl and the serum is celiac)and acute pancreatitis(AP)with hypertriglyceridemia(TG levels of 150-500 mg/dl).Epidemiology suggests that triglyceride-rich lipoproteins(TRL)and their remnants are risk factors for cardiovascular disease and diabetes,while severe hypertriglyceridemia increases the risk of recurrent pancreatitis.Therefore,early and long-term triglyceride-lowering therapy for HTG-AP has its own specificity.This article reviews that new advances in the research and lipid-lowering treatment of HTG-AP.

关 键 词：高甘油三酯血症性急性胰腺炎 冠心病 肾病 肥胖 糖尿病 

分 类 号：R576[医药卫生—消化系统]